In patients with very high cardiovascular risk, a combination therapy of a GLP-1 receptor agonist with a SGLT-2 inhibitor is an attractive option.Mchler, TobiasWiesli, PeterPraxis (16618157)
Nauck, M. AAbd El Aziz, M. SMeier, J. JSpringer Berlin HeidelbergDer DiabetologeNauck M, El Abd AMS, Meier JJ (2016) DPP-4-Hemmer und GLP-1-Rezeptor-Agonisten. Kardiovaskuläre Effekte. Diabetologe. :10.1007/s11428-016-0083-8